APONTIS PHARMA Boosts Forecast with 5-Year Novartis Deal for Asthma Drugs

• APONTIS PHARMA AG has entered a five-year distribution and marketing agreement with Novartis for two asthma medications - The agreement is expected to bring in around EUR 9 million in sales and up to EUR 1.5 million in earnings for the 2024 financial year - As a result, APONTIS PHARMA is raising its forecast for 2024, expecting an increase in sales to EUR 50.7 million and a positive EBITDA of EUR 3.3 million - The CEO of APONTIS PHARMA highlights the importance of the agreement for patient care in Germany - APONTIS PHARMA specializes in Single Pill combinations in Germany, focusing on cardiovascular diseases - For more information, visit https://apontis-pharma.de/en/financial-calendar and https://apontis-pharma.de/en/share-price

APONTIS PHARMA

-0,85 %

+3,14 %

+28,53 %

+87,00 %

-27,75 %

-56,27 %

ISIN:DE000A3CMGM5WKN:A3CMGM

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• Max